Rinath M. Jeselsohn, MD

Rinath M. Jeselsohn, MD, discusses enrollment criteria for the phase 3 VERITAC-2 trial, as well as the potential clinical implications of this research for patients with advanced estrogen receptor–positive/HER2-negative metastatic breast cancer.